Breaking the obesity–cardiovascular
cycle through earlier intervention
During a recent symposium, experts discussed the growing need for earlier intervention in obesity, particularly among patients with elevated cardiovascular (CV) risk, while highlighting the broader impact of obesity on cardiometabolic health, including metabolic dysfunction-associated steatotic liver disease (MASLD). The symposia also examined evolving evidence surrounding semaglutide across the SELECT and STEP clinical trial programmes.
